OptiBiotix Health PLC Licence agreement with Bened Biomedical (1755A)
September 10 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1755A
OptiBiotix Health PLC
10 September 2018
10 September 2018
OptiBiotix Health plc
("OptiBiotix" or "the Company")
Licence agreement with Bened Biomedical
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has entered into a three year
non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan
("Bened"). The agreement grants Bened a non-exclusive license to
produce, package, promote, market, and commercialise products
containing OptiBiotix's cholesterol and blood pressure reducing
strain, LP(LDL) (R), in Taiwan, with the aim of maximising the
financial return for both parties.
OptiBiotix previously announced (RNS: 13 September 2017) the
signing of a Memorandum of Understanding with Bened to explore
licensing and sales opportunities. This announcement confirms the
successful conclusion of those discussions. Bened Biomedical Co.,
Ltd., was founded in 2015 as a spin off from National Yang-Ming
University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a
leading probiotic research and marketing companies in Asia
developing microbiome based products for neuropsychological,
allergic, immunological, metabolic and aging-related disorders.
This agreement expands OptiBiotix's sale into Taiwan with the
potential to broaden the opportunity within the Asia Pacific
region. Cardiovascular disease is the second leading cause of death
in Taiwan, behind Cancer, and is seen as a major public health
issue. The Taiwanese supplements market is predicted to grow by a
27% growth by 2021. The agreement creates a pathway to access
territories in the Asia Pacific region with a total probiotic
retail value of $16.1 billion, of which supplements are $700
million.
Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING
THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June
2017).
Per Rehne, Commercial Director of OptiBiotix, said: "We are
pleased to announce this licence agreement with Bened Biomedical
which opens up the commercial opportunity for LP(LDL) (R) in Taiwan
and the wider Asia Pacific Region. Bened have expressed confidence
in developing and commercialising food supplement containing
LP(LDL) (R) and we see it as an important step to extend global
reach of LP(LDL) (R). This is the 13(th) agreement for LP(LDL) (R)
over the last 18 months.
"This is a strategic step in developing the sales channels into
the Asian probiotic markets and the commercial reach of
OptiBiotix's LP(LDL) (R) strain. Enhancing our presence in Asia
allows OptiBiotix to offer multiple product solutions through
partnerships with consumer health and pharmaceutical companies,
which has the potential to create multiple revenue streams,
including those coming from the newly launched CholBiome products
containing LP(LDL) (R)."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Lianne Cawthorne Mob: 07584 391 303
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRZMGGLDNFGRZM
(END) Dow Jones Newswires
September 10, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024